DK1077703T3 - Orale lægemiddelformer med reproducerbar frisættelse af gatifloxacin eller farmaceutisk anvendelige salte eller hydrater deraf - Google Patents

Orale lægemiddelformer med reproducerbar frisættelse af gatifloxacin eller farmaceutisk anvendelige salte eller hydrater deraf

Info

Publication number
DK1077703T3
DK1077703T3 DK99923491T DK99923491T DK1077703T3 DK 1077703 T3 DK1077703 T3 DK 1077703T3 DK 99923491 T DK99923491 T DK 99923491T DK 99923491 T DK99923491 T DK 99923491T DK 1077703 T3 DK1077703 T3 DK 1077703T3
Authority
DK
Denmark
Prior art keywords
gatifloxacin
hydrates
oral pharmaceutical
pharmaceutical forms
pharmaceutically usable
Prior art date
Application number
DK99923491T
Other languages
English (en)
Inventor
Johannes Bartholomaeus
Juergen Betzing
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Application granted granted Critical
Publication of DK1077703T3 publication Critical patent/DK1077703T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK99923491T 1998-05-09 1999-04-29 Orale lægemiddelformer med reproducerbar frisættelse af gatifloxacin eller farmaceutisk anvendelige salte eller hydrater deraf DK1077703T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19820801A DE19820801A1 (de) 1998-05-09 1998-05-09 Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
PCT/EP1999/002893 WO1999058129A1 (de) 1998-05-09 1999-04-29 Orale arzneiformen mit reproduzierbarer wirkstofffreisetzung von gatifloxacin oder pharmazeutisch verwendbaren salzen oder hydraten

Publications (1)

Publication Number Publication Date
DK1077703T3 true DK1077703T3 (da) 2003-06-23

Family

ID=7867223

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99923491T DK1077703T3 (da) 1998-05-09 1999-04-29 Orale lægemiddelformer med reproducerbar frisættelse af gatifloxacin eller farmaceutisk anvendelige salte eller hydrater deraf

Country Status (27)

Country Link
US (1) US6291462B1 (da)
EP (1) EP1077703B1 (da)
JP (1) JP2002514600A (da)
KR (1) KR100587210B1 (da)
CN (1) CN1198615C (da)
AR (1) AR019279A1 (da)
AT (1) ATE235242T1 (da)
AU (1) AU753482B2 (da)
BR (1) BR9910350A (da)
CA (1) CA2325636A1 (da)
CO (1) CO5050341A1 (da)
DE (2) DE19820801A1 (da)
DK (1) DK1077703T3 (da)
ES (1) ES2195573T3 (da)
HU (1) HUP0101597A3 (da)
IL (1) IL139512A0 (da)
MY (1) MY118569A (da)
NO (1) NO20005385D0 (da)
NZ (1) NZ507968A (da)
PE (1) PE20000480A1 (da)
PL (1) PL343936A1 (da)
PT (1) PT1077703E (da)
RU (1) RU2226394C2 (da)
SK (1) SK16772000A3 (da)
UA (1) UA60364C2 (da)
WO (1) WO1999058129A1 (da)
ZA (1) ZA200006440B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2231275T3 (es) 1999-10-08 2005-05-16 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
US6413969B1 (en) * 2000-09-13 2002-07-02 Bristol-Myers Squibb Company Gatifloxacin pentahydrate
JP4387804B2 (ja) * 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
US6589955B2 (en) * 2001-06-20 2003-07-08 Bristol-Myers Squibb Company Pediatric formulation of gatifloxacin
PT1575951E (pt) 2002-12-06 2014-09-15 Debiopharm Int Sa Compostos heterocíclicos, métodos para os preparar e sua utilização em terapia
EP1608377B1 (en) 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US20050031683A1 (en) * 2003-08-04 2005-02-10 Ashish Kapoor Solid pharmaceutical composition
WO2005021000A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Solid oral dosage forms of gatifloxacin
MY144477A (en) * 2004-03-17 2011-09-30 Novartis Ag Galenic formulations of organic compounds
US8450307B2 (en) * 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
US20060247255A1 (en) * 2005-05-02 2006-11-02 Patel Satishkumar A Method for preparing a stable gatifloxacin composition
CA2617230A1 (en) * 2005-08-02 2007-02-08 Baxter International Inc. Medical products and parenteral formulations
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
CN100415212C (zh) * 2006-07-21 2008-09-03 哈药集团制药总厂 一种含乳酸卡德沙星的口服制剂
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
EP2861608B8 (en) 2012-06-19 2019-06-19 Debiopharm International SA Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
DK3419628T3 (da) 2016-02-26 2021-01-11 Debiopharm Int Sa Medikament til behandling af diabetiske fodinfektioner
ES2944535T3 (es) 2019-02-14 2023-06-22 Debiopharm Int Sa Formulación de afabicina, método para preparar la misma
UA129222C2 (uk) 2019-06-14 2025-02-12 Дебіофарм Інтернешнл С.А. Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH089597B2 (ja) 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
ES2061623T3 (es) * 1987-03-02 1994-12-16 Brocades Pharma Bv Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
UA37214C2 (uk) * 1991-01-30 2001-05-15 Дзе Веллкам Фаундейшн Лімітед Таблетки, що диспергуються у воді, та спосіб їх виготовлення
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
JP2647338B2 (ja) * 1993-02-10 1997-08-27 武田薬品工業株式会社 素錠およびその製造方法
US5436253A (en) * 1993-09-08 1995-07-25 Daiichi Pharmaceutical Co., Ltd. Pyridonecarboxylic acid derivatives and mycotic infections
TW406022B (en) * 1994-12-19 2000-09-21 Daiichi Seiyaku Co Method for producing slow-release granular agents
JP3449658B2 (ja) * 1994-12-21 2003-09-22 杏林製薬株式会社 安定性に優れた８−アルコキシキノロンカルボン酸水和物並びにその製造方法
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation

Also Published As

Publication number Publication date
MY118569A (en) 2004-12-31
CO5050341A1 (es) 2001-06-27
DE59904737D1 (de) 2003-04-30
ES2195573T3 (es) 2003-12-01
ZA200006440B (en) 2002-02-08
JP2002514600A (ja) 2002-05-21
IL139512A0 (en) 2001-11-25
RU2226394C2 (ru) 2004-04-10
BR9910350A (pt) 2001-09-25
HUP0101597A2 (hu) 2001-11-28
SK16772000A3 (sk) 2001-05-10
AR019279A1 (es) 2002-02-13
AU753482B2 (en) 2002-10-17
PT1077703E (pt) 2003-08-29
CN1198615C (zh) 2005-04-27
NO20005385L (no) 2000-10-26
HUP0101597A3 (en) 2003-01-28
NO20005385D0 (no) 2000-10-26
PL343936A1 (en) 2001-09-10
US6291462B1 (en) 2001-09-18
WO1999058129A1 (de) 1999-11-18
EP1077703B1 (de) 2003-03-26
CA2325636A1 (en) 1999-11-18
HK1033281A1 (en) 2001-08-24
AU4035299A (en) 1999-11-29
ATE235242T1 (de) 2003-04-15
CN1300216A (zh) 2001-06-20
KR20010043408A (ko) 2001-05-25
NZ507968A (en) 2002-12-20
KR100587210B1 (ko) 2006-06-08
EP1077703A1 (de) 2001-02-28
UA60364C2 (uk) 2003-10-15
PE20000480A1 (es) 2000-05-20
DE19820801A1 (de) 1999-11-25

Similar Documents

Publication Publication Date Title
ATE235242T1 (de) Orale arzneiformen mit reproduzierbarer wirkstofffreisetzung von gatifloxacin oder pharmazeutisch verwendbaren salzen oder hydraten
DK1273575T3 (da) Diazepan derivater eller salte deraf
DK1674084T3 (da) Forlænget frigivelse af oral dosissammensætning
DK1163207T3 (da) Forbedret fremgangsmåde til fremstillingen af ikke-hygroskopiske salte af L(-)-carnitin
EE200100259A (et) Moksifloksatsiini farmatseutiline preparaat
EE05400B1 (et) Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks
DK1445249T3 (da) Nye bensophenon-derivater eller salte deraf
PT1189916E (pt) N-pirazole agonistas do receptor a2a
NO20030213D0 (no) Anvendelse av D2/D3 reseptor-agonister for behandling av fibromyalgi
NO20021747D0 (no) Blandinger av erytromycinderivater med forlenget frigivelse
NO20003219D0 (no) Oralfarmasøytisk doseringsform med pulsert frigivningsvirkning
NO20021540D0 (no) Sammensetninger med kontrollert frigivelse omfattende nimesulfid
DK1448235T3 (da) Orale, farmaceutiske sammensætninger af 5,8,14-triaza-tetracyclo[10.3.1.0(2,11).0(4.9)]-hexadeca-2(11),3,5,7,9-pentaen med kontrolleret frigivelse
DK1149090T3 (da) Ny krystallinsk form af kaliumsalt af (S)-omeprazol
DK1736158T3 (da) Anvendel af 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin samt de fysiologiske acceptable salte deraf
PT1237559E (pt) Combinacoes farmaceuticas compreendendo um antagonista do receptor p2t e megalatrano
FR2775901B1 (fr) Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments
FI20000780L (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
DK0864579T3 (da) Bismuthsalte af antibiotika fra moenomycingruppen, fremgangsmåde til fremstilling heraf, deres anvendelse samt lægemidler med indhold af sådanne salte
DK1475379T3 (da) Anvendelse af scopinesterderivater til fremstilling af lægemidler
NO20013145D0 (no) Anvendelse av Na-H-bytter-inhibitorer for fremstilling av medikamenter
DK1515959T3 (da) Farmaceutiske salte af reboxetin
EE200100084A (xx) NOS inhibiitorite uued farmatseutilised kasutusv�imalused
DK1071397T3 (da) Levosimendan-holdige lægemidler til oral indgivelse med kontrolleret frisætning af det aktive middel
DK1216253T3 (da) Fremgangsmåde til fremstilling af methylendiphosphonsyrer og salte deraf